Market Overview

UPDATE: Goldman Sachs Raises PT to $32 on Pfizer on Breakup Optionality

Related PFE
MedGenesis Announces Deal with Pfizer Related to Possible Treatments for Parkinson's
Benzinga's Weekend M&A Chatter
Martoma Hit with Nine-Year Prison Sentence (Fox Business)

Goldman Sachs maintained Pfizer, Inc. (NYSE: PFE) with a Buy rating and raises the price target from $30.00 to $32.00.

Goldman Sachs commented, "PFE reported 4Q12 earnings and gave 2013 financial guidance which included highlighting efforts to optimize both the innovation-driven and value-based businesses as distinct entities. On the conference call, PFE management described the two businesses as already being distinct in developed markets. While the two businesses are intertwined in Emerging Markets – which works well in these high-growth geographies – PFE will consider separating the two business models in these markets as they evolve. This potential move supports our long held view that PFE could unlock substantially greater value by breaking up the business into two separately traded companies."

Pfizer closed at $27.70 on Tuesday.

Latest Ratings for PFE

DateFirmActionFromTo
Aug 2014Deutsche BankInitiates Coverage onBuy
Jul 2014BMO CapitalDowngradesOutperformMarket Perform
Jul 2014JefferiesMaintainsBuy

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Price Target Analyst Ratings

 

Related Articles (PFE)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters